First-Time-in-Human Study and Prediction of Early Bactericidal Activity for GSK3036656, a Potent Leucyl-tRNA Synthetase Inhibitor for Tuberculosis Treatment

This first-time-in-human (FTIH) study evaluated the safety, tolerability, pharmacokinetics, and food effect of single and repeat oral doses of GSK3036656, a leucyl-tRNA synthetase inhibitor. In part A, GSK3036656 single doses of 5 mg (fed and fasted), 15 mg, and 25 mg and placebo were administered....

Descripción completa

Detalles Bibliográficos
Autores principales: Tenero, David, Derimanov, Geo, Carlton, Alex, Tonkyn, John, Davies, Matt, Cozens, Simon, Gresham, Stephanie, Gaudion, Alison, Puri, Adeep, Muliaditan, Morris, Rullas-Trincado, Joaquin, Mendoza-Losana, Alfonso, Skingsley, Andrew, Barros-Aguirre, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2019
Materias:
Clinical Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658769/
https://www.ncbi.nlm.nih.gov/pubmed/31182528
http://dx.doi.org/10.1128/AAC.00240-19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658769/
https://www.ncbi.nlm.nih.gov/pubmed/31182528
http://dx.doi.org/10.1128/AAC.00240-19

Ejemplares similares